IMMUNOVANT INC (IMVT) Stock News
NASDAQ:IMVT - Nasdaq - US45258J1025 - Common Stock - Currency: USD
IMVT Latest News, Press Relases and Analysis
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?
Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm
/PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces an investigation into potential breaches of fiduciary duty by the directors and...
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence
The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share.
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Immunovant’s new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially...
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock
On May 28, H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Roivant Sciences Ltd. (NASDAQ:ROIV) while keeping the price target the same at $18. The reiteration comes after the company appointed the current President and COO of Roivant, Dr. Eric Venker as CEO of Immunovant. Roivant Sciences Ltd. (NASDAQ:ROIV) is the founding parent […]
UBS Lowers Price Target on Westlake (WLK), Keeps Buy Rating
On May 28, UBS lowered the firm’s price target on Westlake Corporation (NYSE:WLK) from $118 to $101, while keeping a Buy rating on the stock. The adjustment reflects the near-term challenges for the company’s Performance and Essential Materials (PEM) Segment. The company reported its fiscal first quarter results for 2025 on May 2. The company […]
H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results
On May 27, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio, Inc. (NASDAQ:TRML) while keeping the price target at $50. This comes after the company released promising results from the Phase 2 TRANQUILITY trial of Pacibekitug. Analyst Chen noted the results from the Phase 2 TRANQUILITY trial showed a significant reduction […]
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift
The company is getting a new chief executive and a new chief financial officer amid sweeping changes.
Mentions: ROIV
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated
Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company.
Immunovant Provides Update on Graves’ Disease Development Program
High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-Free...
Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?
We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against other best low cost stocks to buy according to billionaires. Markets are wobbling, and panic is becoming the headline. At times when […]
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The...
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
The companies reported positive results for their lead asset in patients with two rare diseases.
Mentions: ROIV
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose...
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for...
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced.
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves’ disease (GD) and...
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT)...
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept...
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for...
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
Roivant Provides Update on Graves’ Disease Development Program
Mentions: ROIV